EXPAND Study Investigating Erbitux As 1st Line Treatment In Advanced Gastric Cancer Completes Recruitment
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that recruitment has been completed for the pivotal Phase III EXPAND clinical trial investigating the efficacy of Erbitux® (cetuximab) in treating patients with advanced gastric cancer. The international study has recruited more than 870 patients since commencing enrollment in 2008...
Read more on Medical News Today
You must log in to post a comment.